Advertisement
Advertisement

TEVA

TEVA logo

Teva Pharmaceutical Industries Limited - ADR

37.34
USD
Sponsored
+0.53
+1.44%
Aug 21, 15:59 UTC -4
Closed
exchange

After-Market

37.31

-0.03
-0.08%

Teva Pharmaceutical Industries Limited - ADR Profile

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

Info & Links

CEO

Richard D. Francis

Headquarters

124 DVORA HANEVI�a STREET
TEL AVIV, L3 6944020, ISRAEL

Industry

Medical Generic Drugs

Sector

Medical

Website

www.tevapharm.com

Auditor

Kesselman & Kesselman

Share holders

1,738

Employees

33,950

Teva Pharmaceutical Industries Limited - ADR Statistics

Valuation Measures

Market Capitalization2

43.48B

Enterprise Value

56.41B

Enterprise Value/EBITDA(ttm)

22.51

Price to Earnings Ratio(ttm)

16.89

Price to Sales(ttm)

2.48

Price to Book(mrq)

5.53

Price to Cash(ytd)

9.87

Profitability

Gross Margin(ttm)

52.32%

Operating Margin(ttm)

14.68%

Profit Margin(ttm)

3.81%

Return on Equity(ttm)

32.64%

Return on Invested Capital(ttm)

2.67%

Return on Assets(ttm)

6.34%

Income Statement

Revenue(ttm)

17.32B

Revenue Per Share(ttm)

14.86

Gross Profit(ttm)

9.08B

EBITDA(ttm)3

2.51B

Net Income Available to Common(ttm)

707.00M

Diluted EPS(ttm)

0.60

Share Statistics

Beta (5Y Monthly)

0.86

52-Week Change

112.04%

S&P 500 52-Week Change

19.00%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

1.17B

Dividend Yield

0.00%

Float4

1.16B

% Held by Insiders

0.54%

% Held by Institutions

54.05%

Balance Sheet

Total Cash(mrq)

3.65B

Total Cash Per Share(mrq)

3.14

Total Debt(mrq)

16.59B

Total Debt/Equity(mrq)

213.90%

Current Ratio(mrq)

0.88%

Quick Ratio(mrq)

0.67%

Book Value Per Share(mrq)

6.66

Cash Flow

Operating Cash Flow Per Share(ytd)

0.32

Free Cash Flow(ytd)

144.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement